Efficacy and Safety of 0.05% Halometasone/1% Triclosan Cream Versus 0.1% Mometasone Furoate Cream in the Treatment of truncal vitiligo: A Retrospective Study

Abstract

Abstract Objective: To retrospectively evaluate efficacy and safety of 0.05% halometasone/1% triclosan cream (Hal/TCS) in treating truncal vitiligo of children and adolescents. Methods: We retrospectively reviewed the records of children and adolescents with truncal vitiligo treated only with topical Hal/TCS twice daily or only with topical 0.1% mometasone furoate cream (mometasone) twice daily for at least 3 months, and collected relevant data. Efficacy outcomes included patients’ mean repigmentation score after 1- and 3-month treatment calculated based on patients’ repigmentation percentage, and effective rate (percentage of patients with ≥50% repigmentation). Subgroup analyses of patients’ mean repigmentation score based on their age, vitiligo stage, and duration were conducted. Rate of adverse events were calculated. Results: One hundred and twenty-two eligible patients were included, among them, 63 and 59 patients were in the Hal/TCS group and the mometasone group, respectively. After 3 months of treatment, the Hal/TCS group had significantly higher mean repigmentation score and effective rate than the mometasone group (53.49 ± 28.33 vs. 41.46 ± 27.16, P = 0.02; 53.97% vs. 35.59%, P = 0.04, respectively). Patients with shorter disease duration (≤12 months) and patients with progressive vitiligo responded significantly better to the Hal/TCS treatment than patients with longer disease duration and patients with stable vitiligo, respectively. Both treatments were well tolerated and the two treatment groups had comparable rates of adverse events. Conclusions: Short-term Hal/TCS treatment was effective, well-tolerated, and safe in treating vitiligo in the trunk of children and adolescents.